记者丨季媛媛 编辑丨张伟贤 3月17日,对于CRO(医药研发外包服务)龙头昭衍新药(603127.SH,06127.HK)的投资者而言,是一个颇不平静的交易日。 继前一日发布股东减持计划公告后,昭衍新药今日开盘即跳空低开,截至发稿时股价已跌停,市场恐慌情绪可见一斑。 引发此次股价地震的,是一则“清仓式”减持公告:公司股东顾晓磊及其一致行动人顾美芳拟在未来三个月内,通过集中竞价...
Source Link记者丨季媛媛 编辑丨张伟贤 3月17日,对于CRO(医药研发外包服务)龙头昭衍新药(603127.SH,06127.HK)的投资者而言,是一个颇不平静的交易日。 继前一日发布股东减持计划公告后,昭衍新药今日开盘即跳空低开,截至发稿时股价已跌停,市场恐慌情绪可见一斑。 引发此次股价地震的,是一则“清仓式”减持公告:公司股东顾晓磊及其一致行动人顾美芳拟在未来三个月内,通过集中竞价...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.